The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance

F. Lauria, D. Raspadori, M. A. Ventura, D. Rondelli, N. Testoni, P. Tosi, M. Michieli, D. Damiani, M. R. Motta, S. Tura

Research output: Contribution to journalArticle

Abstract

The immunophenotype of 110 adult patients with diagnosis of acute myeloblastic leukemia (AML) was analyzed using a wide panel of monoclonal antibodies (mAbs). Leukemic blasts were tested by applying direct immunofluorescence analysis and dual-fluorescence staining, and two groups of patients were identified: 56/110 (51%) expressing only myeloid antigens (My/AML) and 54/110 (49%) expressing both myeloid and lymphoid antigens (Ly/AML), CD13 and CD33 were expressed in almost all FAB subtypes, whereas CD14, frequently expressed in M4 and M5 subtypes (70%), was rarely expressed in M0 + M1 cases (9%). On the contrary, CD34, expressed in 77% of M0 + M1 cases, was practically absent in M3 and M5 subtypes (6% and 7%, respectively). CD2 and CD7 antigens were found in 34% and 42% of patients respectively, whereas B cell-associated antigens, such as CD10 and CD19, were found in 31% and 18% of patients. Cytogenetic abnormalities characteristically present in AML patients were also analyzed and, except for t(8;21) which was found in both groups of patients, the other abnormalities were frequently found in cases coexpressing lymphoid-associated antigens. Finally, the complete remission (CR) rate, survival and event-free survival were analyzed according to the presence of lymphoid markers and also of some specific antigens such as CD7 and CD34. The only prognostic difference was represented by CD34+ patients who showed a reduction in the CR rate compared with CD34- patients (65% versus 82%) (p = 0.05) which became more evident when the mean intensity of fluorescence was considered. In conclusion, mAbs conjugated with fluorochromes and analyzed by more sophisticated cytometers allow the identification of a higher number of AML cases bearing lymphoid- associated antigens, but this phenotypic coexpression is not associated with biologically distinct forms of leukemia.

Original languageEnglish
Pages (from-to)428-434
Number of pages7
JournalStem Cells
Volume13
Issue number4
Publication statusPublished - 1995

Fingerprint

Acute Myeloid Leukemia
Antigens
CD7 Antigens
Ly Antigens
CD2 Antigens
Fluorescence
Monoclonal Antibodies
Direct Fluorescent Antibody Technique
Fluorescent Dyes
Chromosome Aberrations
Disease-Free Survival
Leukemia
B-Lymphocytes
Survival Rate
Staining and Labeling

Keywords

  • AML surface antigens
  • CD34
  • CD7
  • CR
  • mAbs

ASJC Scopus subject areas

  • Cell Biology

Cite this

Lauria, F., Raspadori, D., Ventura, M. A., Rondelli, D., Testoni, N., Tosi, P., ... Tura, S. (1995). The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells, 13(4), 428-434.

The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. / Lauria, F.; Raspadori, D.; Ventura, M. A.; Rondelli, D.; Testoni, N.; Tosi, P.; Michieli, M.; Damiani, D.; Motta, M. R.; Tura, S.

In: Stem Cells, Vol. 13, No. 4, 1995, p. 428-434.

Research output: Contribution to journalArticle

Lauria, F, Raspadori, D, Ventura, MA, Rondelli, D, Testoni, N, Tosi, P, Michieli, M, Damiani, D, Motta, MR & Tura, S 1995, 'The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance', Stem Cells, vol. 13, no. 4, pp. 428-434.
Lauria F, Raspadori D, Ventura MA, Rondelli D, Testoni N, Tosi P et al. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells. 1995;13(4):428-434.
Lauria, F. ; Raspadori, D. ; Ventura, M. A. ; Rondelli, D. ; Testoni, N. ; Tosi, P. ; Michieli, M. ; Damiani, D. ; Motta, M. R. ; Tura, S. / The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. In: Stem Cells. 1995 ; Vol. 13, No. 4. pp. 428-434.
@article{58960132eb154073a5e409bee2937a98,
title = "The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance",
abstract = "The immunophenotype of 110 adult patients with diagnosis of acute myeloblastic leukemia (AML) was analyzed using a wide panel of monoclonal antibodies (mAbs). Leukemic blasts were tested by applying direct immunofluorescence analysis and dual-fluorescence staining, and two groups of patients were identified: 56/110 (51{\%}) expressing only myeloid antigens (My/AML) and 54/110 (49{\%}) expressing both myeloid and lymphoid antigens (Ly/AML), CD13 and CD33 were expressed in almost all FAB subtypes, whereas CD14, frequently expressed in M4 and M5 subtypes (70{\%}), was rarely expressed in M0 + M1 cases (9{\%}). On the contrary, CD34, expressed in 77{\%} of M0 + M1 cases, was practically absent in M3 and M5 subtypes (6{\%} and 7{\%}, respectively). CD2 and CD7 antigens were found in 34{\%} and 42{\%} of patients respectively, whereas B cell-associated antigens, such as CD10 and CD19, were found in 31{\%} and 18{\%} of patients. Cytogenetic abnormalities characteristically present in AML patients were also analyzed and, except for t(8;21) which was found in both groups of patients, the other abnormalities were frequently found in cases coexpressing lymphoid-associated antigens. Finally, the complete remission (CR) rate, survival and event-free survival were analyzed according to the presence of lymphoid markers and also of some specific antigens such as CD7 and CD34. The only prognostic difference was represented by CD34+ patients who showed a reduction in the CR rate compared with CD34- patients (65{\%} versus 82{\%}) (p = 0.05) which became more evident when the mean intensity of fluorescence was considered. In conclusion, mAbs conjugated with fluorochromes and analyzed by more sophisticated cytometers allow the identification of a higher number of AML cases bearing lymphoid- associated antigens, but this phenotypic coexpression is not associated with biologically distinct forms of leukemia.",
keywords = "AML surface antigens, CD34, CD7, CR, mAbs",
author = "F. Lauria and D. Raspadori and Ventura, {M. A.} and D. Rondelli and N. Testoni and P. Tosi and M. Michieli and D. Damiani and Motta, {M. R.} and S. Tura",
year = "1995",
language = "English",
volume = "13",
pages = "428--434",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance

AU - Lauria, F.

AU - Raspadori, D.

AU - Ventura, M. A.

AU - Rondelli, D.

AU - Testoni, N.

AU - Tosi, P.

AU - Michieli, M.

AU - Damiani, D.

AU - Motta, M. R.

AU - Tura, S.

PY - 1995

Y1 - 1995

N2 - The immunophenotype of 110 adult patients with diagnosis of acute myeloblastic leukemia (AML) was analyzed using a wide panel of monoclonal antibodies (mAbs). Leukemic blasts were tested by applying direct immunofluorescence analysis and dual-fluorescence staining, and two groups of patients were identified: 56/110 (51%) expressing only myeloid antigens (My/AML) and 54/110 (49%) expressing both myeloid and lymphoid antigens (Ly/AML), CD13 and CD33 were expressed in almost all FAB subtypes, whereas CD14, frequently expressed in M4 and M5 subtypes (70%), was rarely expressed in M0 + M1 cases (9%). On the contrary, CD34, expressed in 77% of M0 + M1 cases, was practically absent in M3 and M5 subtypes (6% and 7%, respectively). CD2 and CD7 antigens were found in 34% and 42% of patients respectively, whereas B cell-associated antigens, such as CD10 and CD19, were found in 31% and 18% of patients. Cytogenetic abnormalities characteristically present in AML patients were also analyzed and, except for t(8;21) which was found in both groups of patients, the other abnormalities were frequently found in cases coexpressing lymphoid-associated antigens. Finally, the complete remission (CR) rate, survival and event-free survival were analyzed according to the presence of lymphoid markers and also of some specific antigens such as CD7 and CD34. The only prognostic difference was represented by CD34+ patients who showed a reduction in the CR rate compared with CD34- patients (65% versus 82%) (p = 0.05) which became more evident when the mean intensity of fluorescence was considered. In conclusion, mAbs conjugated with fluorochromes and analyzed by more sophisticated cytometers allow the identification of a higher number of AML cases bearing lymphoid- associated antigens, but this phenotypic coexpression is not associated with biologically distinct forms of leukemia.

AB - The immunophenotype of 110 adult patients with diagnosis of acute myeloblastic leukemia (AML) was analyzed using a wide panel of monoclonal antibodies (mAbs). Leukemic blasts were tested by applying direct immunofluorescence analysis and dual-fluorescence staining, and two groups of patients were identified: 56/110 (51%) expressing only myeloid antigens (My/AML) and 54/110 (49%) expressing both myeloid and lymphoid antigens (Ly/AML), CD13 and CD33 were expressed in almost all FAB subtypes, whereas CD14, frequently expressed in M4 and M5 subtypes (70%), was rarely expressed in M0 + M1 cases (9%). On the contrary, CD34, expressed in 77% of M0 + M1 cases, was practically absent in M3 and M5 subtypes (6% and 7%, respectively). CD2 and CD7 antigens were found in 34% and 42% of patients respectively, whereas B cell-associated antigens, such as CD10 and CD19, were found in 31% and 18% of patients. Cytogenetic abnormalities characteristically present in AML patients were also analyzed and, except for t(8;21) which was found in both groups of patients, the other abnormalities were frequently found in cases coexpressing lymphoid-associated antigens. Finally, the complete remission (CR) rate, survival and event-free survival were analyzed according to the presence of lymphoid markers and also of some specific antigens such as CD7 and CD34. The only prognostic difference was represented by CD34+ patients who showed a reduction in the CR rate compared with CD34- patients (65% versus 82%) (p = 0.05) which became more evident when the mean intensity of fluorescence was considered. In conclusion, mAbs conjugated with fluorochromes and analyzed by more sophisticated cytometers allow the identification of a higher number of AML cases bearing lymphoid- associated antigens, but this phenotypic coexpression is not associated with biologically distinct forms of leukemia.

KW - AML surface antigens

KW - CD34

KW - CD7

KW - CR

KW - mAbs

UR - http://www.scopus.com/inward/record.url?scp=0029026795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029026795&partnerID=8YFLogxK

M3 - Article

C2 - 7549902

AN - SCOPUS:0029026795

VL - 13

SP - 428

EP - 434

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 4

ER -